[go: up one dir, main page]

UY29964A1 - Formas de cristal f,g,h,i, y k del mesilato de imatinib - Google Patents

Formas de cristal f,g,h,i, y k del mesilato de imatinib

Info

Publication number
UY29964A1
UY29964A1 UY29964A UY29964A UY29964A1 UY 29964 A1 UY29964 A1 UY 29964A1 UY 29964 A UY29964 A UY 29964A UY 29964 A UY29964 A UY 29964A UY 29964 A1 UY29964 A1 UY 29964A1
Authority
UY
Uruguay
Prior art keywords
crystal form
crystal forms
warm
methyl
preparation
Prior art date
Application number
UY29964A
Other languages
English (en)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY29964A1 publication Critical patent/UY29964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a la forma de cristal-F, la forma de cristal-G, la forma de cristal-H, la forma de cristal-I, y la forma de cristal-K de la sal de adición de ácido metansulfónico de la 4-(4-metil-piperazin.1-ilmetil)-N-(4-metil-3-(4-(piridin-3-il)-pirimidin-2-ilamino)-fenil)-benzamida, a ciertos procesos para su preparación, a composiciones farmacéuticas que contienen estas formas de cristal, a su uso en métodos de diagnóstico o para el tratamiento terapéutico de animales de sangre caliente, y a su uso como un intermediario o para la preparación de preparaciones farmacéuticas para utilizarse en métodos de diagnóstico para el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
UY29964A 2005-11-25 2006-11-23 Formas de cristal f,g,h,i, y k del mesilato de imatinib UY29964A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001705P 2005-11-28 2005-11-28
US74001605P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
UY29964A1 true UY29964A1 (es) 2007-06-29

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29964A UY29964A1 (es) 2005-11-25 2006-11-23 Formas de cristal f,g,h,i, y k del mesilato de imatinib

Country Status (13)

Country Link
US (6) US7893076B2 (es)
EP (3) EP2546248A1 (es)
JP (2) JP5844508B2 (es)
KR (4) KR20130141712A (es)
CN (1) CN102351842B (es)
AU (2) AU2006316823A1 (es)
BR (1) BRPI0618993A2 (es)
CA (3) CA2628330C (es)
EC (1) ECSP088473A (es)
MY (1) MY146403A (es)
NO (1) NO20082684L (es)
UY (1) UY29964A1 (es)
WO (1) WO2007059963A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
CA2628330C (en) * 2005-11-25 2015-06-16 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
JP2010540465A (ja) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド 安定なイマチニブ組成物
RU2365587C1 (ru) * 2008-02-22 2009-08-27 Закрытое Акционерное Общество "Фарм-Синтез" Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
US10478290B2 (en) * 2013-11-26 2019-11-19 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
US8048883B2 (en) 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
AU2005249159A1 (en) 2004-06-04 2005-12-15 Bioniche Life Sciences Inc. Use of imatinib to treat liver disorders and viral infections
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
MY148375A (en) * 2005-08-26 2013-04-15 Novartis Ag Delta and epsilon crystal forms of imatinib mesylate
CA2628330C (en) * 2005-11-25 2015-06-16 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
KR20130141712A (ko) 2013-12-26
WO2007059963A1 (en) 2007-05-31
JP5844508B2 (ja) 2016-01-20
CA2824301C (en) 2016-01-12
US20110171301A1 (en) 2011-07-14
AU2011201286A1 (en) 2011-04-07
KR20130137721A (ko) 2013-12-17
US20080268040A1 (en) 2008-10-30
NO20082684L (no) 2008-08-15
CA2824301A1 (en) 2007-05-31
US20130224288A1 (en) 2013-08-29
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
US20120226038A1 (en) 2012-09-06
US20120015955A1 (en) 2012-01-19
CA2628330C (en) 2015-06-16
CN102351842A (zh) 2012-02-15
CA2824307A1 (en) 2007-05-31
EP2578580A1 (en) 2013-04-10
EP1960380A1 (en) 2008-08-27
KR20130140909A (ko) 2013-12-24
MY146403A (en) 2012-08-15
JP2009517353A (ja) 2009-04-30
BRPI0618993A2 (pt) 2011-09-20
US20120015027A1 (en) 2012-01-19
US8198289B2 (en) 2012-06-12
CA2628330A1 (en) 2007-05-31
KR20080078804A (ko) 2008-08-28
US8846706B2 (en) 2014-09-30
US8592440B2 (en) 2013-11-26
CN102351842B (zh) 2014-07-23
CA2824307C (en) 2016-03-29
AU2006316823A1 (en) 2007-05-31
ECSP088473A (es) 2008-06-30
JP2014074067A (ja) 2014-04-24
US8507515B2 (en) 2013-08-13
EP2546248A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
ECSP088473A (es) FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
CO6382134A2 (es) Sales y formas de cristal del 2-metil-2-[4-(metil-2-oxo-8-quinolin-3-3il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]propionitrilo
CY1124519T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ (S)-4-(8-ΑΜΙΝΟ-3-(1-(ΒΟΥΤ-2-ΥΝΟΫΛΟ)ΠΥΡΡΟΛΙΔΙΝ-2-ΥΛΟ) ΙΜΙΔΑΖΟ[1,5-α|ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ) ΒΕΝΖΑΜΙΔΙΟΥ
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PE20150998A1 (es) Inhibidores de histona demetilasas
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
MX348290B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
GT200500307A (es) Compuestos quimicos
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
UY29633A1 (es) Derivados de oxindol
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112014011981A8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
CR9722A (es) Derivados de benzilpiperazina y su uso medico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161212